...for people prescribed the products for medical reasons. Not for the general populace (in case anyone only reads the headline). > In particular, female and c

...for people prescribed the products for medical reasons. Not for the general populace (in case anyone only reads the headline). > In particular, female and cannabis-naïve patients are at increased likelihood of experiencing adverse events. It's not surprising that naive patients would experience more adverse events, as prior exposure to cannabis would have pre-selected for people willing or unwilling to take a prescribed cannabis medication. > In total there were 5176 (182.70%) AEs reported by 474 (16.73%) patients. The mean number of AEs reported per patient was 1.83 ± 6.82. When categorized by severity, most AEs were mild (n = 2201; 77.69%) or moderate (n = 2239; 79.03%), in contrast to severe (n = 730; 25.77%), and life threatening/disabling (n = 6; 0.21%). The most frequently reported AEs were fatigue (n = 409; 14.42%) and dry mouth (n = 347; 12.25%), followed by somnolence (n = 312; 11.01%), lethargy (n = 308; 10.87%), insomnia (n = 299; 10.55%), headache (n = 297; 10.48%), concentration impairment (n = 286; 10.10%), nausea (n = 242; 8.54%), and dizziness (n = 228; 8.05%). The adverse events are described in full in Supplementary Table 2. ----------- > The mean number of AEs across the observation period was 1.83, while only 16.73% of participants experienced an AE. Thus, it appears a minority of patients are experiencing AEs, however those who experience AEs are likely to experience multiple AEs. ... > Another explanation may be that patients were treated with various concentrations and combinations of cannabinoids ----------- > Subsequent multivariate analysis found female gender (OR = 1.77 [95% CI: 1.41–2.24], p < 0.001) to be associated with increased probability of experiencing an AE, while current consumption of cannabis (OR = 0.45 [95% CI: 0.34–0.60]; p < 0.001) was associated with a reduced risk of experiencing an AE > A clinical trial previously demonstrated that females experienced the same acute effects as males despite administering less cannabis and achieving lower blood concentrations of THC and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [Citation44]. Moreover, sex hormones have been suggested to affect the expression of CB1 receptors in the central nervous system [Citation45]. So the male bias in medicine strikes again. With females more likely to be overdosed or improperly dosed. ----------- > Improvement was also seen separately in each subscale of EQ-5D-5L, including mobility, self-care, usual activities, pain or discomfort, and anxiety or depression, at 1 month, 3 months, and 6 months (p < 0.050). At 12 months, improvement was seen in all subscales except self-care (p = 0.078).